Effect of trastuzumab/AT-101 combination on apoptosis and cytotoxicity in HER2-positive breast cancer cells: A novel combination to effect resistance to anti-HER2 therapy through inhibition of PI3K signaling.

Karaca, BurcakBozkurt, EmirAtmaca, RadiceSurmeli, ZakPinar, AtikeSanil, Ulus AliUslu, Ruchan2019-10-272019-10-2720140732-183X1527-7755https://doi.org/10.1200/jco.2014.32.15_suppl.e13512https://hdl.handle.net/11454/5009950th Annual Meeting of the American-Society-of-Clinical-Oncology -- MAY 30-JUN 03, 2014 -- Chicago, ILen10.1200/jco.2014.32.15_suppl.e13512info:eu-repo/semantics/closedAccessEffect of trastuzumab/AT-101 combination on apoptosis and cytotoxicity in HER2-positive breast cancer cells: A novel combination to effect resistance to anti-HER2 therapy through inhibition of PI3K signaling.Conference Object3215WOS:000358613200214Q1